VistaGen Therapeutics
VTGN
112 hedge funds and large institutions have $110M invested in VistaGen Therapeutics in 2022 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 33 increasing their positions, 36 reducing their positions, and 22 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
76% more call options, than puts
Call options by funds: $2.47M | Put options by funds: $1.41M
0.05% more ownership
Funds ownership: 2.18% → 2.24% (+0.05%)
8% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 36
9% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 22
3% less funds holding
Funds holding: 116 → 112 (-4)
34% less capital invested
Capital invested by funds: $168M → $110M (-$57.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
+$5.47M |
| 2 |
CC
Commodore Capital
New York
|
+$3.47M |
| 3 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$3.13M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$971K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$823K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.95M |
| 2 |
Norges Bank
Oslo,
Norway
|
-$1.64M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$1.63M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$1.24M |
| 5 |
Morgan Stanley
New York
|
-$701K |
VTGN Hedge Fund Activity: Q2 2022 in Review
112 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q2 2022, worth a combined $110M — down 34% from $168M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of VTGN and 20 opened new positions — a net loss of 2 holders — while 36 trimmed existing stakes and 33 added.
The largest buyer was VR Adviser, adding an estimated $5.47M. The largest seller was Sphera Funds Management, cutting an estimated $1.95M.
- 112 institutional investors held VistaGen Therapeutics (VTGN) as of Q2 2022, down from 116 in Q1 2022.
- Funds reported $110M of VistaGen Therapeutics stock for Q2 2022, down 34% quarter-over-quarter.
- 20 funds opened new VistaGen Therapeutics positions in Q2 2022 and 22 closed out, a net change of -2 holders.
- The largest VistaGen Therapeutics buyer in Q2 2022 was VR Adviser, an estimated $5.47M added.
- The largest VistaGen Therapeutics seller in Q2 2022 was Sphera Funds Management, an estimated $1.95M sold.
Based on aggregated 13F filings for Q2 2022.